Diligence memo · auto-generated · as of July 2, 2026
Nautilus Neurosciences, Inc.
Nautilus Neurosciences, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Nautilus Neurosciences, Inc. operates in Pharmaceuticals, based in BRIDGEWATER.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Nautilus Neurosciences, Inc. has raised $53M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $18M on 2009-11-23.
Most recent recorded round closed around 2010-03-31.
Valuation (modeled)modeled
Provath models Nautilus Neurosciences, Inc. at approximately $272M (range $17M–$1.0B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.37× the median modeled value of Series B Pharmaceuticals companies in 2010–2012 (47 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 1 months.
Last raise 16.3 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.6× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 82% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 73% of those peers.
Closest niche peers: Celator Pharmaceuticals Inc, Kythera Biopharmaceuticals Inc, Palatin Technologies Inc, Pernix Therapeutics Holdings, Inc., CEBIX Inc.
Peoplefiled
11 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.